PMID- 22723658
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20161125
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 14
IP  - 8
DP  - 2012 Aug
TI  - A case-control study of determinants for the occurrence of gouty arthritis in 
      heart failure patients.
PG  - 916-21
LID - 10.1093/eurjhf/hfs086 [doi]
AB  - AIMS: Gouty arthritis is a frequent and disabling complication in heart failure 
      patients. This study aimed to investigate which factors are associated with the 
      occurrence of gouty arthritis in these patients. METHODS AND RESULTS: A 
      case-control study was performed in heart failure patients (February 2007 to 
      October 2009). Cases were defined as patients with gouty arthritis. Factors that 
      are possibly associated with gouty arthritis and/or heart failure were evaluated. 
      Echocardiographic dimensions and laboratory values including glomerular 
      filtration rate (GFR) and fractional excretion of uric acid (FEUA) were measured. 
      Logistic regression analysis was used to determine crude and adjusted odds ratios 
      (ORs) and 95% confidence intervals (CIs) for possibly associated factors. In 
      total, 188 patients (59 with gouty arthritis) were included. Spironolactone use 
      was associated with a decreased occurrence of gouty arthritis (OR 0.32, 95% CI 
      0.13-0.77). Independently associated with an increased occurrence of gouty 
      arthritis were hypertensive heart failure (OR 3.6, 95% CI 1.6-8.2), New York 
      Heart Association (NYHA) class III/IV (OR 4.5, 95% CI 1.8-11.0), lower GFR (P < 
      0.001), and FEUA <4% (OR 3.3, 95% CI 1.4-7.9). Among the four age/gender groups, 
      the strongest association with gouty arthritis was found in men <65 years. 
      CONCLUSION: Our identification of factors that are associated with the occurrence 
      of gouty arthritis makes it possible to develop strategies to improve further the 
      quality of life in heart failure patients. The possible decreased occurrence of 
      gouty arthritis in spironolactone users has to be confirmed in prospective 
      studies.
FAU - Hueskes, Berdine A A
AU  - Hueskes BA
AD  - Department of Rheumatology, Rijnstate, 6883 AZ Velp, The Netherlands.
FAU - Willems, Frank F
AU  - Willems FF
FAU - Leen, Aukelien C
AU  - Leen AC
FAU - Ninaber, Patricia A
AU  - Ninaber PA
FAU - Westra, Richard
AU  - Westra R
FAU - Mantel-Teeuwisse, Aukje K
AU  - Mantel-Teeuwisse AK
FAU - Janssens, Hein J E M
AU  - Janssens HJ
FAU - van de Lisdonk, Eloy H
AU  - van de Lisdonk EH
FAU - Roovers, Elisabeth A
AU  - Roovers EA
FAU - Janssen, Matthijs
AU  - Janssen M
LA  - eng
PT  - Journal Article
DEP - 20120621
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 0 (Sodium Potassium Chloride Symporter Inhibitors)
RN  - 27O7W4T232 (Spironolactone)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - Arthritis, Gouty/diagnostic imaging/*etiology/pathology
MH  - Case-Control Studies
MH  - Confidence Intervals
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Heart Failure/*complications/diagnostic imaging/drug therapy/pathology
MH  - Humans
MH  - Kidney/drug effects
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sodium Potassium Chloride Symporter Inhibitors/therapeutic use
MH  - Spironolactone/therapeutic use
MH  - Ultrasonography
EDAT- 2012/06/23 06:00
MHDA- 2012/12/12 06:00
CRDT- 2012/06/23 06:00
PHST- 2012/06/23 06:00 [entrez]
PHST- 2012/06/23 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - hfs086 [pii]
AID - 10.1093/eurjhf/hfs086 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2012 Aug;14(8):916-21. doi: 10.1093/eurjhf/hfs086. Epub 2012 
      Jun 21.